Switching to Iloperidone From Other Antipsychotics in Schizophrenia

Completed · Phase 4

Conditions studied: Schizophrenia

In brief

Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, olanzapine, or aripiprazole due to suboptimal efficacy and/or safety/tolerability reasons.

Key facts

Study ID

NCT01207414

Run by

Novartis

People needed

501

Starts

2010-08-01

Expected to finish

2012-01-01

Last updated by the study team

2013-03-15

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females, 18 to 64 years of age, inclusive
• DSM-IV diagnosis of schizophrenia
• Patients currently on an optimal in-label dose of one of the following permitted antipsychotic treatments for at least 30 days: risperidone, olanzapine, or aripiprazole
• Efficacy Clinical Global Impression of Severity (E-CGI-S) of 4 or 5 or
• Not tolerating one of the permitted treatments and exhibits one of the allowable side-effects

You may not qualify if…

• Any other current Axis I disorder other than schizophrenia which is the focus of treatment;
• Acutely psychotic or patient's symptom severity requires hospitalization
• Patient with significant cardiovascular illness (myocardial infarction, cardiac arrhythmia)
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Comprehensive Neuroscience — Cerritos, California, United States
• ATP Clinical Research Center, Inc. — Costa Mesa, California, United States
• Collaborative Neuroscience Network — Garden Grove, California, United States
• Apostle Clinical Trials, Inc. — Long Beach, California, United States
• Pacific Health Systems — National City, California, United States
• Pacific Research Partners — Oakland, California, United States
• Excell Research, Inc. — Oceanside, California, United States
• University of California, Irvine — Orange, California, United States
• CNRI San Diego — San Diego, California, United States
• Affiliated Research Institute — San Diego, California, United States
• Artemis Institute for Clinical Research — San Diego, California, United States
• Neuropsychiatric Research Center of Orange County — Santa Ana, California, United States
• Viking Clinical Research — Temecula, California, United States
• Collaborative Neuroscience — Torrance, California, United States
• The Hospital of Central Connecticut — New Britain, Connecticut, United States
• Comprenhensive Neuroscience — Washington D.C., District of Columbia, United States
• Amit K. Vijapura MD & Associates — Jacksonville, Florida, United States
• Scientific Clinical Research — North Miami, Florida, United States
• Atlanta Center for Medical Research — Atlanta, Georgia, United States
• Comprehensive Neuroscience — Atlanta, Georgia, United States
• Northwest Behavioral Research Center — Marietta, Georgia, United States
• Carman Research — Smyrna, Georgia, United States
• Institute for Behavioral Medicine — Smyrna, Georgia, United States
• Alexian Brothers Center for Mental Health — Arlington Heights, Illinois, United States
• Birmingham Psychiatry Pharmaceutical Studies, Inc. — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.